MedPath

Does the addition of recLH (Luveris) to a regimen of recFSH (Gonal-F) and GnRH antagonist (Cetrotide) improve ovarian response and implantation rates in patients age >35 years undergoing IVF/ET?

Conditions
Subfertile women undergoing IVF or ICSI, age > 35 years
Registration Number
NL-OMON29497
Lead Sponsor
VU University Medical Center, Devision of Reproductive Medicine
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
600
Inclusion Criteria

Age >35 years undergoing IVF or ICSI for any indication.

Exclusion Criteria

Women with PCOS.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath